Acute generalized exanthematous pustulosis

Last updated
Acute generalized exanthematous pustulosis
Other namesToxic pustuloderma, pustular drug eruption
Acute generalized exanthematous pustulosis.jpg
Acute generalized exanthematous pustulosis
Specialty Dermatology

Acute generalized exanthematous pustulosis (AGEP; also known as pustular drug eruption and toxic pustuloderma) is a rare skin reaction that in 90% of cases is related to medication.

Contents

AGEP is characterized by sudden skin eruptions that appear on average five days after a medication is started. These eruptions are pustules, i.e. small red white or red elevations of the skin that contain cloudy or purulent material (pus). [1] The skin lesions usually resolve within 1–3 days of stopping the offending medication. [2] However, more severe cases are associated with a more persistent disorder that may be complicated by secondary skin infections and/or involvement of the liver, lung, and/or kidney. [3]

Severe cutaneous adverse reaction (SCAR) disorders are regarded as the drug-induced activation of T cells which then initiate innate immune responses that are inappropriately directed against self tissues. Studies on the DRESS syndrome, Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS/TEN overlap indicate that many individuals are predisposed to develop these reactions to a particular medication based on their genetically determined expression of particular human leukocyte antigen (i.e. HLA) alleles or T-cell receptors and/or their efficiencies in adsorbing, distributing to tissues, metabolizing, and/or eliminating) a particular SCARS-inducing medication. Evidence for these predispositions in AGEP has not been as well-established. [2] [4] [5]

Signs and symptoms

AGEP is an acute drug eruption characterized by numerous small, primarily non-follicular, sterile skin pustules arising within large areas of red swollen skin usually within days of taking an inciting drug. [6] The skin eruptions are often pruritic and accompanied by fever, headache, a high number of neutrophils and eosinophils in the blood, and elevated blood levels of markers for inflammation (i.e. erythrocyte sedimentation rate and C-reactive protein). The skin eruptions typically end within a week after causative drug is discontinued. [3]

Rare cases of lung and bone marrow involvement have also been reported to complicate AGEP. [3] [7] However, involvement of these organs typically resolve along with the skin eruptions. AGEP typically shows a mild course: usually, it is not associated with life-threatening complicates although superinfections of skin lesions may be serious or even life-threatening. AGEP has a mortality rate of less than 5%. [2] [7] [8]

Cause

About 90% of AGEP reactions are associated with medications. The remaining cases of AGEP have been associated with infective and other agents. [7]

Medicines

The most frequently reported drugs that have been associated with the development of AGEP include penicillin, aminopenicillins, macrolides, quinolones, sulfonamides, hydroxychloroquine, terbinafine, and diltiazem. [7] A more complete list of drugs sorted by their intended actions are: [3] [7] [9] [10] [11]

Microbe infections

Infections with Parvovirus B19, mycoplasma, cytomegalovirus, coxsackie B4 virus, Epstein-Barr virus (EBV), [13] [14] Chlamydophila pneumoniae , E. coli , and Echinococcus have been reported to be associated with the development of AGEP in the absence of an apparent drug-induced cause. The pathophysiology for the development of these drug-independent cases of AGEP is unclear. [7] Viral infections have also been observed to be associated with the development of SJS, SJS/TEN, and TEN in the absence of a causative drug. [7] [10] [15]

Other agents

Herbal medications, spider bites, iopamidol (used for radiocontrast), lacquers, mercury, psoralen (combined with ultraviolet A to treat psoriasis), and xenobiotics have been associated with the development of AGEP in case reports. [11]

Pathophysiology

Like other drug-induced SCARs disorders, AGEP is a type IV hypersensitivity reaction in which a drug or its metabolite stimulates cytotoxic T cells (i.e. CD8+ T cells) or T helper cells (i.e. CD4+ T cells) to initiate autoimmune reactions that attack self tissues. SCARs are type IV, subtype IVb (DRESS syndrome), type IV, subtype IVc (SJS, SJS/TEN, TEN), or type IV, subtype IVd (AGEP) hypersensitivity reactions. AGEP therefore differs from the other SCARs disorders in that it involves the tissue-injuring action of inappropriately activated neutrophils and the excessive production of cytokines which stimulate production of, recruit to tissues, and/or activation of neutrophils (Interleukin 8, Interleukin 17, GM-CSF) and promote innate immune and autoimmune responses (Interleukin 22). [2] [7] [8]

AGEP also differs from the other SCARs disorders in respect to the level of evidence supporting the underlying mechanism by which a drug or its metabolite stimulates CD8+ T or CD4+ T cells. Studies indicate that the mechanism by which a drug or its metabolites accomplishes this stimulation involves subverting the antigen presentation pathways of the innate immune system. A drug or metabolite covalently binds with a host protein to form a non-self, drug-related epitope. An antigen-presenting cell (APC) takes up these proteins; digests them into small peptides; places the peptides in a groove on the human leukocyte antigen (i.e. HLA) component of their major histocompatibility complex (i.e. MHC) (APC); and presents the MHC-associated peptides to the T-cell receptor on CD8+ T or CD4+ T cells. Those peptides expressing a drug-related, non-self epitope on their HLA-A, HLA-B, HLA-C, HLA-DM, HLA-DO, HLA-DP, HLA-DQ, or HLA-DR proteins may bind to a T-cell receptor to stimulate the receptor-bearing parent T cell to attack self tissues. Alternatively, a drug or metabolite may also stimulate T cells by inserting into the groove on a HLA protein to serve as a non-self epitope, bind outside of this groove to alter a HLA protein so that it forms a non-self epitope, or bypass the APC by binding directly to a T cell receptor. However, non-self epitopes must bind to specific HLA serotypes to stimulate T cells and the human population expresses some 13,000 different HLA serotypes while an individual expresses only a fraction of them. Since a SCARs-inducing drug or metabolite interacts with only one or a few HLA serotypes, their ability to induce SCARs is limited to those individuals who express HLA serotypes targeted by the drug or metabolite. [5] [8] Thus, only rare individuals are predisposed to develop SCARs in response to a particular drug on the basis of their expression of HLA serotypes. [16] Studies have identified several HLA serotypes associated with development of DRESS syndrome, SJS, SJS/TEN, and TEN in response to various drugs which elici these disorders, developed tests to identify individuals who express these serotypes, and thereby determined that these individuals should avoid the offending drug. HLA serotypes associated with AGEP and specific drugs have not been identified. [5] A study conducted in 1995 identified of HLA-B51, HLA-DR11, and HLA-DQ3 of unknown serotypes to be associated with development of AGEP but the results have not been confirmed, expanded to identify the serotypes involved, nor therefore useful in identifying individuals predisposed to develop AGEP in response to any drug. [2] Similarly, a specific T cell receptor variant has been associated with the development of DRESS syndrome, SJS, SJS/TEN, and TEN but not AGEP. [2] [17]

Variations in ADME, i.e. an individual's efficiency in absorbing, distributing, metabolizing, and excreting a drug) has been found to occur in cases of the DRESS syndrome, SJS, SJS/TEN, and TEN. These variations influence the levels and duration of a drug or drug metabolite in tissues and thereby impact the drug's or drug metabolite's ability to evoke SCARs. [18]

In rare cases, the development of AGEP has been reported to occur in individuals with loss of function mutations in their IL36RN gene. This gene codes for the interleukin 36 receptor antagonist (IL36RA). IL36RA blocks the pro-inflammatory actions of Interleukin-36 cytokines (viz., IL-36α, IL-36β and IL-36γ) on keratinocytes, synoviocytes, dendritic cells, macrophages, and T cells. It does so by binding to, but not stimulating, these cytokines' receptors, IL1RL2 and IL1RAP, thereby interfering with the interleukin-36 cytokines' binding to and stimulating IL1RL2 and IL1RAP. However, the IL36RN loss of function mutation has been reported in cases of generalized pustular psoriasis. [3] [19] The presence of this mutation in two seemingly unrelated disorders has led to suggestions that the classification of AGEP as a SCARs or a form of psoriasis requires study. [19]

Diagnosis

The diagnosis of AGEP may be forthright in typical cases in which an individual: has taken a drug known to cause the disorder; develops multiple sterile pustules overlying large areas of red swollen skin starting a few days after initial drug intake; and has a histology of biopsied lesions that shows pustules just below the skin's Stratum corneum (outermost layer), apoptotic (i.e. necrotic) keratinocytes, spongiosis of the stratum spinosum, and infiltration of these tissues by neutrophils plus, in many but not all cases, eosinophils. [7] Many cases of AGEP, however, present less clear cut clinical features of the disorder. AGEP must be differentiated from generalized pustular psoriasis (GPP) with which it shares many clinical and histological features. A history of psoriasis, the presence of typical psoriatic skin lesions at the time of diagnosis, and histological evidence in skin lesions of necrotic keratinocytes, neutrophil-rich infiltrates, eosinophil infiltrates, and/or lack of tortuous or dilated blood vessels favors a diagnosis of to AGEP. [20] Other conditions sometimes confused with AGEP include pustular eruptions caused by bacteria, funguses, herpesviridae, and the varicella zoster virus (i.e. causative agent of chicken pox).

Several tests have been proposed to be useful for supporting the diagnosis of and/or implicating a particular drug as the cause of AGEP particularly in individuals who develop skin lesions while taking multiple drugs. These include patch tests in which small amounts of suspect drugs absorbed on patches are applied to the skin; skin allergy tests in which drugs are applied by skin prick or intradermal injection; and oral provocation in which drugs are taken in a single small dose orally. These tests have not been widely adopted because of their insensitivity and, most particular with oral provocation tests, the possibility of causing a relapse or worsening or the disorder. In vitro tests, including mixed lymphocyte reaction tests in which the response of individuals' blood mononuclear cells to suspect drugs and ELISPOT tests in which specific drug-reactive lymphocytes or their drug-induced release of AGEP mediators (e.g. interferon-γ interleukin 4, or granulysin) are measured have likewise not been broadly adopted because of their lack of specificity. [8]

Classification

The disorder is classified in the group of severe cutaneous adverse reactions (i.e. SCARs). The SCARs group of disorders includes four other drug-induced skin reactions: drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and Stevens–Johnson/toxic epidermal necrolysis overlap syndrome (SJS/TEN). SJS, SJS/TEN, and TEN, while initially described as distinct adverse drug-induced cutaneous reactions are now regarded as manifestations of epidermal necrolysis differing only in extent of skin involvement. While all of five SCARs disorders are potentially lethal, AGEP has the lowest mortality of the group. [2] [7]

Treatment

The treatment of AGEP begins with the immediate cessation of the offending drug. For individuals developing AGEP while taking multiple drugs, non-essential drugs should be discontinued and essential drugs should be replaced by chemically unrelated drugs that are used as alternatives to the discontinued drug(s). In cases of multiple drug intake, skin and/or in vitro testing may be of some use in identifying the offending drug. Beyond identifying and discontinuing the offending drug, individuals with mild symptoms may require no further treatment. Those troubled by more significant symptoms such as itching or fever may require antihistamines, topical corticosteroids, systemic corticosteroids, and/or antipyretics. Individuals with liver, lung, kidney, and/or severe skin complications may require high dosage systemic corticosteroids and organ-specific interventions. Skin infections, which may lead to sepsis, are potentially lethal complications of AGEP; preventative methods and rapid treatment of such infections with appropriate antibiotics and, where needed, further supportive measures are critical in the treatment of this complication. Overall, however, AGEP has a lethality of less than 5% with recent reports showing no fatalities. Typically, individuals with AGEP have rapid rates of recovery even in when experiencing the cited complications. [3] [8] [9] [21]

See also

Related Research Articles

Stevens–Johnson syndrome (SJS) is a type of severe skin reaction. Together with toxic epidermal necrolysis (TEN) and Stevens–Johnson/toxic epidermal necrolysis (SJS/TEN) overlap, they are considered febrile mucocutaneous drug reactions and probably part of the same spectrum of disease, with SJS being less severe. Erythema multiforme (EM) is generally considered a separate condition. Early symptoms of SJS include fever and flu-like symptoms. A few days later, the skin begins to blister and peel, forming painful raw areas. Mucous membranes, such as the mouth, are also typically involved. Complications include dehydration, sepsis, pneumonia and multiple organ failure.

<span class="mw-page-title-main">Psoriasis</span> Skin disease

Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin. These areas are red, pink, or purple, dry, itchy, and scaly. Psoriasis varies in severity from small localized patches to complete body coverage. Injury to the skin can trigger psoriatic skin changes at that spot, which is known as the Koebner phenomenon.

<span class="mw-page-title-main">Allopurinol</span> Medication

Allopurinol is a medication used to decrease high blood uric acid levels. It is specifically used to prevent gout, prevent specific types of kidney stones and for the high uric acid levels that can occur with chemotherapy. It is taken orally or intravenously.

<span class="mw-page-title-main">Toxic epidermal necrolysis</span> Severe skin reaction involving fever, blistering, and peeling

Toxic epidermal necrolysis (TEN), also known as Lyell's syndrome, is a type of severe skin reaction. Together with Stevens–Johnson syndrome (SJS) it forms a spectrum of disease, with TEN being more severe. Early symptoms include fever and flu-like symptoms. A few days later the skin begins to blister and peel forming painful raw areas. Mucous membranes, such as the mouth, are also typically involved. Complications include dehydration, sepsis, pneumonia, and multiple organ failure.

<span class="mw-page-title-main">Staphylococcal scalded skin syndrome</span> Medical condition

Staphylococcal scalded skin syndrome (SSSS) is a dermatological condition caused by Staphylococcus aureus.

<span class="mw-page-title-main">Febrile neutrophilic dermatosis</span> Medical condition

Sweet syndrome (SS), or acute febrile neutrophilic dermatosis, is a skin disease characterized by the sudden onset of fever, an elevated white blood cell count, and tender, red, well-demarcated papules and plaques that show dense infiltrates by neutrophil granulocytes on histologic examination.

<span class="mw-page-title-main">Tetrazepam</span> Chemical compound

Tetrazepam is a benzodiazepine derivative with anticonvulsant, anxiolytic, muscle relaxant and slightly hypnotic properties. It was formerly used mainly in Austria, France, Belgium, Germany and Spain to treat muscle spasm, anxiety disorders such as panic attacks, or more rarely to treat depression, premenstrual syndrome or agoraphobia. Tetrazepam has relatively little sedative effect at low doses while still producing useful muscle relaxation and anxiety relief. The Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human endorsed the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation to suspend the marketing authorisations of tetrazepam-containing medicines across the European Union (EU) in April 2013. The European Commission has confirmed the suspension of the marketing authorisations for Tetrazepam in Europe because of cutaneous toxicity, effective from the 1 August 2013.

Drug rash with eosinophilia and systemic symptoms or drug reaction with eosinophilia and systemic symptoms (DRESS), also termed drug-induced hypersensitivity syndrome (DIHS), is a rare reaction to certain medications. It involves primarily a widespread skin rash, fever, swollen lymph nodes, and characteristic blood abnormalities such as an abnormally high level of eosinophils, low number of platelets, and increased number of atypical white blood cells (lymphocytes). However, DRESS is often complicated by potentially life-threatening inflammation of internal organs and the syndrome has about a 10% mortality rate. Treatment consists of stopping the offending medication and providing supportive care. Systemic corticosteroids are commonly used as well but no controlled clinical trials have assessed the efficacy of this treatment.

<span class="mw-page-title-main">HLA-B58</span> Human leukocyte antigen serotype

HLA-B58 (B58) is an HLA-B serotype. B58 is a split antigen from the B17 broad antigen, the sister serotype B57. The serotype identifies the more common HLA-B*58 gene products. B*5801 is associated with allopurinol induced inflammatory necrotic skin disease.

<span class="mw-page-title-main">Drug eruption</span> Medical condition

In medicine, a drug eruption is an adverse drug reaction of the skin. Most drug-induced cutaneous reactions are mild and disappear when the offending drug is withdrawn. These are called "simple" drug eruptions. However, more serious drug eruptions may be associated with organ injury such as liver or kidney damage and are categorized as "complex". Drugs can also cause hair and nail changes, affect the mucous membranes, or cause itching without outward skin changes.

<span class="mw-page-title-main">Pustulosis palmaris et plantaris</span> Medical condition

Pustulosis palmaris et plantaris is a chronic recurrent pustular dermatosis localized on the palms and soles only, characterized histologically by intraepidermal pustules filled with neutrophils. It can occur as part of the SAPHO syndrome.

<span class="mw-page-title-main">Allopurinol hypersensitivity syndrome</span> Medical condition

Allopurinol hypersensitivity syndrome(AHS) typically occurs in persons with preexisting kidney failure. Weeks to months after allopurinol is begun, the patient develops a morbilliform eruption or, less commonly, develops one of the far more serious and potentially lethal severe cutaneous adverse reactions viz., the DRESS syndrome, Stevens Johnson syndrome, or toxic epidermal necrolysis. About 1 in 1000 patients receiving allopurinol are affected, and mortality rates have been reported to be between 20% and 25%.

<span class="mw-page-title-main">Generalized bullous fixed drug eruption</span> Medical condition

Generalized bullous fixed drug eruption (GBFDE) most commonly refers to a drug reaction in the erythema multiforme group. These are uncommon reactions to medications, with an incidence of 0.4 to 1.2 per million person-years for toxic epidermal necrolysis and 1.2 to 6.0 per million person-years for Stevens–Johnson syndrome. The primary skin lesions are large erythemas, most often irregularly distributed and of a characteristic purplish-livid color, at times with flaccid blisters.

Stasis papillomatosis is a disease characterized by chronic congestion of the extremities, with blood circulation interrupted in a specific area of the body. A consequence of this congestion and inflammation is long-term lymphatic obstruction (lymphedema). It is also typically characterized by the appearance of numerous papules. Injuries can range from small to large plates composed of brown or pink, smooth or hyperkeratotic papules. The most typical areas where injuries occur are the back of the feet, the toes, the legs, and the area around a venous ulcer formed in the extremities, although the latter is the rarest of all. These injuries include pachydermia, lymphedema, lymphomastic verrucosis and elephantosis verrucosa. The disease can be either localized or generalized; the localized form makes up 78% of cases. Treatment includes surgical and pharmaceutical intervention; indications for partial removal include advanced fibrotic lymphedema and elephantiasis. Despite the existence of these treatments, chronic venous edema, which is a derivation of stasis papillomatosis, is only partially reversible. The skin is also affected and its partial removal may mean that the skin and the subcutaneous tissue are excised. A side effect of the procedure is the destruction of existing cutaneous lymphatic vessels. It also risks papillomatosis, skin necrosis and edema exacerbation.

Interleukin 36, or IL-36, is a group of cytokines in the IL-1 family with pro-inflammatory effects. The role of IL-36 in inflammatory diseases is under investigation.

NSAIDhypersensitivity reactions encompass a broad range of allergic or allergic-like symptoms that occur within minutes to hours after ingesting aspirin or other NSAID nonsteroidal anti-inflammatory drugs. Hypersensitivity drug reactions differ from drug toxicity reactions in that drug toxicity reactions result from the pharmacological action of a drug, are dose-related, and can occur in any treated individual. Hypersensitivity reactions are idiosyncratic reactions to a drug. Although the term NSAID was introduced to signal a comparatively low risk of adverse effects, NSAIDs do evoke a broad range of hypersensitivity syndromes. These syndromes have recently been classified by the European Academy of Allergy and Clinical Immunology Task Force on NSAIDs Hypersensitivity.

Severe cutaneous adverse reactions (SCARs) are a group of potentially lethal adverse drug reactions that involve the skin and mucous membranes of various body openings such as the eyes, ears, and inside the nose, mouth, and lips. In more severe cases, SCARs also involves serious damage to internal organs.

The p-i concept refers to the pharmacological interaction of drugs with immune receptors. It explains a form of drug hypersensitivity, namely T cell stimulation, which can lead to various acute inflammatory manifestations such as exanthems, eosinophilia and systemic symptoms, Stevens–Johnson syndrome, toxic epidermal nercrolysis, and complications upon withdrawing the drug.

Neonatal pustular eruptions are a group of disorders characterized by various forms of pustulosis seen in the first four weeks of life.

References

  1. ↑ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN   0-7216-2921-0.: 124 
  2. 1 2 3 4 5 6 7 Hoetzenecker W, Nägeli M, Mehra ET, Jensen AN, Saulite I, Schmid-Grendelmeier P, Guenova E, Cozzio A, French LE (2016). "Adverse cutaneous drug eruptions: current understanding". Seminars in Immunopathology. 38 (1): 75–86. doi:10.1007/s00281-015-0540-2. PMID   26553194. S2CID   333724.
  3. 1 2 3 4 5 6 Alniemi DT, Wetter DA, Bridges AG, El-Azhary RA, Davis MD, Camilleri MJ, McEvoy MT (2017). "Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996-2013". International Journal of Dermatology. 56 (4): 405–414. doi:10.1111/ijd.13434. PMID   28084022. S2CID   21325754.
  4. ↑ Halevy S (August 2009). "Acute generalized exanthematous pustulosis". Curr Opin Allergy Clin Immunol. 9 (4): 322–8. doi:10.1097/ACI.0b013e32832cf64e. PMID   19458527. S2CID   205434868.
  5. 1 2 3 Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA, Phillips EJ (2017). "Pharmacogenomics of off-target adverse drug reactions". British Journal of Clinical Pharmacology. 83 (9): 1896–1911. doi:10.1111/bcp.13294. PMC   5555876 . PMID   28345177.
  6. ↑ Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. pp. 297, 303, 308, 309, 470. ISBN   978-1-4160-2999-1.
  7. 1 2 3 4 5 6 7 8 9 10 Feldmeyer L, Heidemeyer K, Yawalkar N (July 2016). "Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy". International Journal of Molecular Sciences. 17 (8): 1214. doi: 10.3390/ijms17081214 . PMC   5000612 . PMID   27472323.
  8. 1 2 3 4 5 Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O (2017). "Severe cutaneous adverse reactions to drugs". Lancet. 390 (10106): 1996–2011. doi:10.1016/S0140-6736(16)30378-6. PMID   28476287. S2CID   9506967.
  9. 1 2 Thienvibul C, Vachiramon V, Chanprapaph K (2015). "Five-Year Retrospective Review of Acute Generalized Exanthematous Pustulosis". Dermatology Research and Practice. 2015: 260928. doi: 10.1155/2015/260928 . PMC   4689982 . PMID   26783390.
  10. 1 2 Szatkowski J, Schwartz RA (November 2015). "Acute generalized exanthematous pustulosis (AGEP): A review and update". Journal of the American Academy of Dermatology. 73 (5): 843–8. doi:10.1016/j.jaad.2015.07.017. PMID   26354880.
  11. 1 2 Choi MJ, Kim HS, Park HJ, Park CJ, Lee JD, Lee JY, Kim HO, Park YM (May 2010). "Clinicopathologic manifestations of 36 Korean patients with acute generalized exanthematous pustulosis: a case series and review of the literature". Annals of Dermatology. 22 (2): 163–9. doi:10.5021/ad.2010.22.2.163. PMC   2883418 . PMID   20548906.
  12. ↑ "HYDROXYZINE HYDROCHLORIDE tablet". Daily Med. U.S. National Library of Medicine. Retrieved 25 October 2020.
  13. ↑ Ropars, Nolwenn; Darrieux, Laure; Tisseau, Laurent; Safa, Gilles (2014-09-28). "Acute generalized exanthematous pustulosis associated with primary Epstein-Barr virus infection". JAAD Case Reports. 1 (1): 9–11. doi:10.1016/j.jdcr.2014.09.004. ISSN   2352-5126. PMC   4802527 . PMID   27075126.
  14. ↑ "Acute generalised exanthematous pustulosis | DermNet NZ". dermnetnz.org. Retrieved 2021-01-14.
  15. ↑ Lerch M, Mainetti C, Terziroli Beretta-Piccoli B, Harr T (February 2018). "Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis". Clinical Reviews in Allergy & Immunology. 54 (1): 147–176. doi:10.1007/s12016-017-8654-z. PMID   29188475. S2CID   46796285.
  16. ↑ Pichler WJ, Hausmann O (2016). "Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms". International Archives of Allergy and Immunology. 171 (3–4): 166–179. doi: 10.1159/000453265 . PMID   27960170.
  17. ↑ Wang CW, Dao RL, Chung WH (2016). "Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions". Current Opinion in Allergy and Clinical Immunology. 16 (4): 339–45. doi:10.1097/ACI.0000000000000286. PMID   27362322. S2CID   9183824.
  18. ↑ Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MS, Phillips EJ (November 2017). "Recent advances in the understanding of severe cutaneous adverse reactions". The British Journal of Dermatology. 177 (5): 1234–1247. doi:10.1111/bjd.15423. PMC   5582023 . PMID   28256714.
  19. 1 2 Bachelez H (January 2018). "Pustular psoriasis and related pustular skin diseases". The British Journal of Dermatology. 178 (3): 614–618. doi:10.1111/bjd.16232. PMID   29333670. S2CID   4436573.
  20. ↑ Orime M (2017). "Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions". Journal of Immunology Research. 2017: 6928363. doi: 10.1155/2017/6928363 . PMC   5684554 . PMID   29226159.
  21. ↑ Canadian Medical Association Journal, September 15, 2009, pp 393-396
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.